ABArvind Bagga

Arvind Bagga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arvind Bagga has a total of 434 co-authors. Here are the top co-authors by number of shared publications:

  • Pankaj Hari

    Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    66 shared publications
  • Aditi Sinha

    Division of Nephrology, Department of Pediatrics, ICMR Advanced Center for Research in Nephrology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    65 shared publications
  • Priyanka Khandelwal

    Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    26 shared publications
  • Ashima Gulati

    Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

    15 shared publications
  • Mukta Mantan

    Department of Pediatrics, Maulana Azad Medical College and Lok Nayak Jai Prakash Hospital, New Delhi, India

    11 shared publications
  • Amit K. Dinda

    Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

    9 shared publications

Latest Publications

  • Age at onset and cumulative initial prednisolone dose predict frequent relapses in steroid-sensitive nephrotic syndrome: an individual participant data systematic review and meta-analysis of placebo-controlled RCTs

    by Aditi Sinha, Mani Kalaivani, Rebecca Woolley, Nynke Teeninga, Nicholas J. A. Webb, Michiel F. Schreuder, Arvind Bagga

    Based on evidence from high-quality RCTs, current guidelines recommend that the initial episode of childhood-onset steroid-sensitive nephrotic syndrome be treated with prednisolone for 8-12 weeks. However, the relative impact of extended versus standard prednisolone therapy on outcomes requires evaluation alongside patient characteristics known to affect disease course. To examine whether extending the duration of therapy for the initial episode of childhood-onset nephrotic syndrome reduces the risk of first and frequent relapses and annual relapse rate and whether sex, age at onset, ethnicity, time to remission, and cumulative prednisolone dose modify, confound, or independently influence these measures. PubMed, Embase, and Cochrane Central Register. Placebo-controlled RCTs, published during 1980-2024, that compared extended (> 12 weeks) to standard (8-12 weeks) prednisolone therapy in pediatric patients at onset of steroid-sensitive nephrotic syndrome and for which individual participant data (IPD) was made available. Patients, 1-18 years old, treated with predniso(lo)ne for the first episode of steroid-sensitive nephrotic syndrome. Cochrane Risk of Bias 2 tool; two- and one-stage IPD analyses. This systematic review and IPD meta-analysis examined the time to first relapse and frequent relapses (estimated as hazard ratios, HR (95% CI)) and annual relapse rate following extended or standard therapy with prednisolone in pediatric patients with the initial episode of steroid-sensitive nephrotic syndrome. One-stage and two-stage IPD analyses examined sex, age, ethnicity, and time to remission as effect modifiers, confounders, and covariates of treatment effect. The IPD meta-analyses included 529 of 568 patients from three RCTs; 49% and 51% participants received extended and standard therapy, respectively. On two-stage meta-analysis, compared to standard therapy, extended therapy was associated with delayed first relapse (HR 0.80 (0.65, 0.97)) but not frequent relapses (0.92 (0.73, 1.17)), and similar annual relapse rate (MD 0.07 (-0.09, 0.23)). Extended therapy postponed the first relapse, but not frequent relapses, in patients < 2.5 years old and those of Asian or non-Western European ethnicity. Adjusted IPD meta-analyses did not find benefit of extended therapy in reducing the risks of first or frequent relapses. Multivariate one-stage meta-analyses showed that older age (≥ 2.5 years) and higher cumulative initial prednisolone dose (≥ 3.135 g/m2) were associated with reduced risk of first and frequent relapses. Few studies; heterogeneity in duration of therapy among studies and study eligibility; inability to examine the independent impact of dose and duration on outcomes. Age at onset and cumulative initial dose of prednisolone, and not duration of extended therapy, determine disease course in pediatric steroid-sensitive nephrotic syndrome. The benefit of extending initial therapy on risk of first and frequent relapses in young patients requires examination in controlled trials using BSA-based dosing. PROSPERO CRD42021291537.

  • A systematic review of short-term outcomes in patients with anti–factor H associated atypical HUS managed with plasma exchanges versus eculizumab

    by Aditi Sinha, Tanvi Bindal, Federica Zotta, Anne-Laure Sellier-Leclerc, Julien Hogan, Pankaj Hari, Marina Vivarelli, Arvind Bagga

    Antibodies to factor H (anti-FH) are a leading cause of atypical hemolytic uremic syndrome (aHUS) in school-going children. While terminal complement blockade with eculizumab (ECZ) is standard of care for all forms of aHUS, anti-FH associated aHUS is uniquely amenable to combination therapy with plasma exchange (PEX) and immunosuppression. There are no controlled comparisons on the relative short- or medium-term efficacy of the two strategies of management. The primary objectives were to compare the time from initiation of therapy to hematological remission and renal recovery between patients managed with PEX versus ECZ, with or without immunosuppression, for anti-FH associated aHUS in native kidneys. We also compared the proportions of patients attaining hematological remission or renal recovery by 7, 14 and 28 days of therapy, and proportion of patients with chronic kidney disease G1-5, dialysis-dependence, or death. PubMed and Embase were searched from January 2004 to April 2025. Studies, in English language, were eligible if they reported the time to hematological remission and renal recovery in individual patients with anti-FH antibody-associated aHUS in native kidneys and treated with either PEX or ECZ with or without additional immunosuppression. Within studies, individual patients were included if they had received either, and not both, PEX or ECZ, and information regarding time to hematological remission and renal recovery was available. The risk of bias for retrospective cohort studies and case reports or series was assessed using the Newcastle-Ottawa Quality Assessment Scale and Joanna Briggs Institute (JBI) tool for systematic reviews, respectively. Individual patient data were combined by therapy group to report time-to-event outcomes as hazard ratios (95% confidence intervals, CI), compared using the log rank test. Other continuous measures were compared between groups using the rank sum test. Fourteen of 57 studies shortlisted from among 403 search results met eligibility criteria, within which 99 patients, including 81 managed with PEX and 18 with ECZ, with/without immunosuppression, were eligible. Patients receiving PEX presented later with more severe anemia and lower eGFR, and more often required dialysis. Median time to hematologic remission was significantly shorter with PEX (9 vs. 20 days; P = 0.0007) while time to renal recovery was similar (16 vs. 20 days; P = 0.36). The proportion with CKD G3-5 and mortality was insignificantly higher with PEX than ECZ (respective P 0.077 and 0.36). Our findings are limited by small numbers of participants and studies, lack of comparative studies, heterogeneity in disease severity, and variations in definitions of outcomes. Patients managed with PEX achieved hematological remission faster than those on ECZ; the time to renal recovery was similar. Given the precautions and vigilance necessary with complement blockade, PEX appears to be a satisfactory initial choice for managing anti-FH associated HUS, particularly in low-resource settings. Prospective trials should compare the efficacy, safety and healthcare costs of these strategies in managing patients with anti-FH associated HUS. PROSPERO ID: CRD420251033150.

  • AsPNA Clinical Practice Guidelines for the management of infection-related glomerulonephritis

    by Jitendra Meena, Aditi Sinha, Sudarsan Krishnasamy, Agnes A. Alba, Madiha A. Aziz, Afroza Begum, Eugene Yu-Hin Chan, Jameela A. Kari, Anirut Pattaragarn, Inoka Perera, et al.

    Infection-related glomerulonephritis (IRGN) is the leading cause of acute glomerulonephritis (GN) in children worldwide, particularly in low- and middle-income countries. To provide evidence-based care, the Glomerular Disease Workgroup of the Asian Pediatric Nephrology Association (AsPNA) convened a panel of experts to develop recommendations on diagnosis, evaluation and management of pediatric IRGN. Following a comprehensive literature search, available evidence was graded using the AAP-GRADE approach, and recommendations finalized through Delphi consensus. The panel recommends diagnosing acute GN in children presenting with hematuria and proteinuria, if accompanied with edema, oliguria, or hypertension. Postinfectious GN is suspected in patients with acute GN with recent streptococcal or staphylococcal infection and transient hypocomplementemia. The evaluation includes urinalysis, kidney function tests, serum albumin, complement C3, blood counts and kidney ultrasonography. Kidney biopsy is required for patients with atypical features, nephrotic syndrome, persistently low C3 beyond 12 weeks, and/or rapidly progressive GN. Therapy is chiefly supportive, including fluid and salt restriction in patients with edema or hypertension, diuretics for volume overload, and calcium channel blockers for stage 2 hypertension. Patients with significant edema, severe hypertension, or acute kidney injury require inpatient monitoring. Patients with staphylococcus-associated GN infective endocarditis associated GN and shunt nephritis require therapy with antibiotics. Immunosuppressive therapy is suggested in patients with crescentic IRGN or rapidly progressive course. All patients with IRGN, particularly those with crescentic GN or rapidly progressive GN, require long-term monitoring of serum creatinine, urinalysis and blood pressure. These guidelines intend to provide a structured, evidence-informed approach for the management of patients with IRGN.


  • Prevalence and types of anti-neutrophil cytoplasmic antibodies in patients with nephrotic syndrome treated with levamisole

    by Puneet Singh, Aditi Sinha, Uma Kumar, Vineeta Batra, Pankaj Hari, Arvind Bagga

    Background Levamisole is a commonly used steroid-sparing medication in pediatric nephrotic syndrome. While use of this agent is associated with development of antineutrophil cytoplasmic antibodies (ANCA), there is limited data on their prevalence and antigen specificity. Methods This cross-sectional study, conducted from October 2020 to June 2022, included 117 patients, aged 2–18 years, with steroid-sensitive nephrotic syndrome and receiving levamisole at a dose of 2–2.5 mg/kg on alternate days for ≥ 6-months. All patients were screened for ANCA by indirect immunofluorescence and conventional ELISA. Patients positive on screening underwent profile ELISA to determine its antigen specificity. Results Twenty (17.1%) patients tested positive for ANCA by either screening method. On profile ELISA, antibodies showed specificity to myeloperoxidase (n = 13), human neutrophil elastase (n = 6), proteinase-3 (n = 4), and/or their combination (n = 3). Risk factors independently associated with presence of ANCA included female sex [adjusted odds ratio (aOR) 3.1; 95% CI 1.0–9.3; P = 0.044] and cumulative prednisolone intake in the last 6-months [aOR 0.0041; 0.0001–0.21; P = 0.006]. Following levamisole discontinuation, ANCA was negative in all 16 patients who were retested at 40.6 (3–67.2) months. Antinuclear and anticardiolipin antibodies were present in 19 and 8 patients, respectively, and leukopenia in 4 patients. Conclusions A significant proportion of patients with steroid-sensitive nephrotic syndrome receiving > 6-months’ therapy with levamisole show positive ANCA, with antigen specificity against myeloperoxidase, neutrophil elastase and/or proteinase-3. The risk was higher in girls and lower in those receiving concurrent therapy with prednisolone in the past 6-months. Stopping levamisole therapy was associated with resolution of ANCA. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Open Access

    Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome

    by Tiffany Tu, Alejandro Ochoa, Amika Sood, Ashley Drabik, Megan Chryst-Stangl, Brandon Lane, Guanghong Wu, Frank Donovan, Ursula Harper, Settara Chandrasekharappa, et al.

    Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract


  • Open Access

    Anasarca in Juvenile Dermatomyositis: An Uncommon Presentation

    by Gautham Pai, Shreya Adavalath, Nafeesa Afnan, Amit Kumar Satapathy, Aditi Sinha, Arvind Bagga

  • Open Access

    Eculizumab for Atypical Hemolytic Uremic Syndrome: Guidance for Developing Countries

    by Tanvi Bindal, Aditi Sinha, Arvind Bagga

    Hemolytic uremic syndrome (HUS) is a heterogeneous group of disorders with the underlying pathology of thrombotic microangiopathy (TMA). With regional decline in Shiga toxin associated HUS, atypical HUS (aHUS) characterized by severe AKI, relapsing illness and extrarenal features, is increasingly identified. Since most such cases are mediated by dysregulation of the alternate complement pathway, the term complement-mediated TMA is preferred. Plasma exchanges (PEX) constitute the cornerstone of therapy of aHUS in developing countries, including for patients with anti-FH antibodies, the chief cause of pediatric aHUS in the subcontinent. However, worldwide experience with eculizumab during the past decade reports considerably better outcomes in patients with significant variants in genes encoding key complement regulators. With eculizumab poised to enter the Indian market, this article provides detailed guidance on its use. Indications for its rational use are discussed, including issues related to dosage, mode of administration, and side-effects of eculizumab and related agents. Therapy with eculizumab should be instituted promptly, with particular attention to dosage and frequency of administration. The article provides clear advice regarding meningococcal, pneumococcal and other vaccines, and the need for antibiotic prophylaxis during and following therapy with eculizumab. It also underscores key aspects for monitoring patients on complement blockade, and updates guidelines regarding discontinuation of complement inhibitors following remission, and in context of kidney transplantation. Both PEX and eculizumab are important options for managing patients with aHUS, with the choice dictated by the underlying cause, and ability to sustain either therapy in adequate doses and for sufficient duration for relapse-free outcomes.


  • MicroRNAs in idiopathic childhood nephrotic syndrome

    by Aditi Sinha, Manraj Sra, Aijaz Ahmed, Saumyaranjan Mallick, Himanshi Saini, Kshetrimayum Ghanapriya Devi, Pankaj Hari, Arvind Bagga

    Background miRNAs are non-coding RNA that are recognized as biomarkers of kidney disorders. There is limited information on the differential expression of miRNA and their target genes in idiopathic nephrotic syndrome of childhood. Methods We enrolled patients, 2–18 years old, with steroid-sensitive nephrotic syndrome, either at onset or during relapse, and steroid-resistant disease, at diagnosis of steroid-resistance. Patients with steroid-sensitive disease were off immunosuppressive medications, while those with steroid-resistance were on therapy with prednisolone at enrollment. Controls were healthy children attending the hospital for vaccinations or for minor non-infectious, non-kidney ailments. Following RNA extraction from whole blood, differential expression of 2549 miRNAs was examined to identify differentially expressed miRNA, defined as those with absolute log2 fold change > 2 and adjusted P < 0.05. Target genes, predicted using miRNet, were compared against the genes for nephrotic syndrome in the NCBI database, and the ontology of selected genes was examined using DAVID. Results Comparison of miRNA expression in 36 patients and 12 controls led to the identification of 62 and 12 differentially expressed miRNA in patients with steroid-sensitive and steroid-resistant disease, respectively. Of 76 miRNAs that were differentially regulated between the two disease categories, 26 were unique to steroid-sensitive disease and 11 to steroid-resistance. Of 5955 and 2813 genes targeted by the miRNAs specific to steroid-sensitive and steroid-resistant nephrotic syndrome, respectively, 79 were relevant in context of the disease. Conclusion Steroid-sensitive and steroid-resistant nephrotic syndrome have distinct miRNA expression profiles, which can be examined as biomarkers and in pathogenetic pathways.


  • Etiology, clinical profile, and outcomes of crescentic glomerulonephritis in children: a systematic review

    by Jitendra Meena, Parnika Nangla, Sanjay Ojha, Aditi Sinha, Pankaj Hari, Arvind Bagga

    Crescentic glomerulonephritis, if not managed promptly, is associated with unsatisfactory outcomes. There are limited studies reporting the outcomes of crescentic glomerulonephritis in children. This systematic review is aimed at synthesizing the data on etiology, clinical profile, and outcomes of crescentic glomerulonephritis in children. We performed a literature search using PubMed, Embase, and Web of Science from inception to January 2024 without language or geographic restrictions. Cohort and cross-sectional studies with at least 10 participants reporting etiology, clinical features, and outcomes on crescentic glomerulonephritis in children were considered eligible. Children aged less than 18 years with crescentic glomerulonephritis. We used a tool by Hoy et al. for assessing the quality of studies. We calculated pooled estimates using random effect meta-analyses. Primary outcome was the pooled proportion of patients progressing to kidney failure. From 1706 records, we included 36 studies (1548 participants) from 16 countries. Etiology was immune-complex glomerulonephritis in 76% (95% CI 67 to 85), pauci-immune in 19% (13 to 25), and anti-GBM disease in 5% (3 to 7) of patients. Gross hematuria, oliguria, edema, and hypertension were observed in 63% (41 to 82), 57% (34 to 79), 79% (65 to 90), and 64% (49 to 77), respectively. In-hospital mortality, reported in 11 studies, was 7% (4 to 11). Progression to kidney failure and chronic kidney disease was reported in 27% (21 to 33) and 50% (29 to 71) of patients, respectively. Risk factors for kidney failure included oliguria, dialysis requirement at onset, estimated GFR, proportion of fibrous crescents, and pauci-immune glomerulonephritis as the underlying etiology. High heterogeneity in pooled estimates of the outcomes. Immune-complex glomerulonephritis is the most common etiology in children, with edema, hypertension, gross hematuria, and oliguria being the chief presenting manifestations. Almost one in every four patients with crescentic glomerulonephritis progressed to kidney failure. PROSPERO registration number CRD42024500515.


  • Open Access

    Editorial

    by Arvind Bagga